Home > Oncology > ASCO 2021 > Gastrointestinal Cancers > Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer

Pembrolizumab benefits survival in MSI-H/dMMR metastastic colorectal cancer

Presented By
Prof. Thierry André, Sorbonne University, France
Conference
ASCO 2021
Trial
Phase 3, KEYNOTE 177
First-line treatment of patients with microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC) with pembrolizumab improved overall survival, but the prespecified threshold for significance was not reached. These were the final results of the phase 3 KEYNOTE 177 trial. Immune checkpoint blockade has a predicted clinical benefit in patients with MSI-H/dMMR mCRC [1]. In the phase 3 KEYNOTE 177 trial (NCT02563002), 307 treatment-naïve patients with MSI-H/dMMR mCRC were randomly assigned 1:1 to receive pembrolizumab (200 mg every 3 weeks up to 35 cycles) or chemotherapy every 2 weeks. Results from an interim analysis showed significant prolonged progression-free survival in patients treated with pembrolizumab versus chemotherapy (median 16.6 months vs 8.2 months) [2]. Prof. Thierry André (Sorbonne University, Fra...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on